TACSTD2 and prostate cancer: In prostate cancer xenografts, Trop2 was upregulated in relapsed tumors after flutamide and docetaxel treatment and Trop2 enhanced recovery of androgen-sensitive, but not androgen-resistant cells, after exposure to docetaxel [145].